Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVX 701

Drug Profile

AVX 701

Alternative Names: AVX701; Cancer vaccine VRP-CEA - AlphaVax; Carcinoembryonic antigen [CEA(6D)]-expressing virus-like replicon particle (VRP) immunotherapy - AlphaVax; CEA(6D) VRP vaccine - AlphaVax; VRP-CEA vaccine - AlphaVax

Latest Information Update: 22 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; Duke University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 01 Jul 2019 Duke University completes a phase I trial in Colorectal cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT01890213)
  • 22 Sep 2015 Phase-I development for Colorectal cancer (Late-stage disease, Second-line therapy or greater) is ongoing in USA (NCT01890213)
  • 30 Nov 2013 Duke University initiates enrolment in a phase I trial for Colorectal cancer (late-stage disease) in the USA (NCT01890213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top